Rationale and design of teravic-4 study: A phase III, randomized clinical trial to evaluate the effects of treatment duration with peginterferon alfa-2a (40-kDa) and ribavirin in naïve patients with chronic hepatitis C virus infection without early virological response at week 4

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 24, Issue 9, 2002, Pages 579-584

  Sanchez Tapias J M ^a   Crespo, J ^b   Diago, M ^c   Perez R ^d   Romero Gomez M ^e   Munoz Sanchez M ^f  

^a HOSPITAL CLÍNIC   (Spain)

^b HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^d HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^e HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^f Roche Farma SA   (Spain)

Author keywords

Amplicor HCV test v.2.0.; Combination therapy; Early response; HCV RNA; Hepatitis C; Hepatitis C virus (HCV); Peginterferon alfa 2a (40 kDa); Ribavirin; Sustained response; TeraViC 4

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN;

ADULT; AGED; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; ENZYME ACTIVITY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; RANDOMIZED CONTROLLED TRIAL; VIROLOGY;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; POLYETHYLENE GLYCOLS; RESEARCH DESIGN; RIBAVIRIN; TIME FACTORS;

EID: 0036873602     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Wilkinson, T. Hepatitis C virus: Prospects for future therapies. Curr Opin Investig Drugs 2001, 2: 1516-22.
2. Shiffman, M.L. Management of interferon therapy nonresponders. Clin Liver Dis 2001, 5: 1025-43.
3. Poynard, T., Leroy, V., Cohard, M. et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration. Hepatology 1996, 24: 778-89.
4. McHutchison, J. Therapy of chronic hepatitis C. Standard treatment of standard patient; update on viral hepatitis. Postgraduate course. AASLD 2000: 136-42.
5. Perry, C. M., Jarvis, B. Peginterferon-alpha-2a (40kD): A review of its use in the management of chronic hepatitis C. Drugs 2001, 61: 2263-88.
6. Zeuzem, S., Heathcote, J.E., Martin, N., Nieforth, K., Modi, M. Peginterferon alfa-2a (40 kDa) monotherapy: A novel agent for chronic hepatitis C therapy. Expert Opin Investig Drugs 2001, 10: 2201-13.
7. Zeuzem, S., Feinman, S.V., Rasenack, J. et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000, 343: 1666-72.
8. Heathcote, E. J., Shiffman, M. L., Cooksley, W.G. et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000, 343: 1673-80.
9. Hadziyannis, S., Cheinquer, H., Morgan, T. et al. Peginterferon alfa-2a (40KD) (PEGASYS) in combination with ribavirin (RBV): Efficacy and safety results from a phase III, randomized, doubleblind, multicentre study examining effect of duration of treatment and RBV dose. 37th Annual Meeting of the European Association for hte Study of the Liver 2002: Abst 536.
10. Fried, M.W., Shiffman, M., Reddy, K.R. et al. Pegylated (40 KDA) interferon alfa-2a (Pegasys®) in combination with ribavirin: Efficacy and safety results from a phase III, randomized, actively-controlled, multicenter study. Dig Dis Week 2001: Abst 289.
11. Ferenci, P., Shiffman, M.L., Fried, M.W. et al. Early prediction of response to 40 KDA peginterferon alfa-2a (Pegasys®) plus ribavirin (RBV) in patients with chronic hepatitis C (CHC). 52nd Annual Meeting AASLD 2001: Abst 716.
12. EASL International Consensus Conference on hepatitis C. Paris, 26-27 February 1999. Consensus statement. J Hepatol 1999, 31: 3-8.
13. Tran, T.T., Martin, P. Chronic Hepatitis C. Curr Treat Options Gastroenterol 2001, 4: 503-10.
14. Bellobuono, A., Mondazzi, L., Tempini, S. et al. Should patients with early loss of serum HCV-RNA during alpha interferon therapy for chronic hepatitis C be treated for 6 or 12 months? J Hepatol 1999, 30: 8-13.
15. Zeuzem, S., Schmidt, J.M., Lee, J.H., van Wagner, M., Teuber, G., Roth, W.K. Hepatitis C virus dynamics in vivo: Effect of ribavirin and interferon alfa on viral turnover. Hepatology 1998, 28: 245-52.
16. Knolle, P.A., Kremp, S., Höhler, T., Krummenauer, F., Schirmacher, P., Gerken, G. Viral and host factors in the prediction of response to interferon-alpha therapy in chronic hepatitis C after long-term follow-up. J Viral Hep 1998, 5: 399-406.
17. Gomez-Rubio, M., Porres, J.C., Castillo, I., Quiroga, J.A., Moreno, A., Carreno, V. Prolonged treatment (18 months) of chronic hepatitis C with recombinant alpha-interferon in comparison with a control group. J Hepatol 1990, 11: S63-7.